Tardive dyskinesia: summary of a Task Force Report of the American Psychiatric Association. By the Task Force on Late Neurological Effects of Antipsychotic Drugs.

No abstract is available for this paper.

• Publication year

  1980

• Venue

  American Journal of Psychiatry

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1176/ajp.137.10.1163PMID 6106389
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An experimental model of tardive dyskinesia

  2005cited by this paper
• An assessment of tardive dyskinesia in schizophrenic outpatients

  1979cited by this paper
• Withdrawal syndromes associated with antipsychotic drugs.

  1978cited by this paper
• Neuroleptic-induced prolactin level elevation and breast cancer: an emerging clinical issue.

  1978cited by this paper
• A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome.

  1978cited by this paper
• Drug history and tardive dyskinesia.

  1978cited by this paper
• Tardive dyskinesia and psychotropic drug history

  1978cited by this paper
• Tardive dyskinesia: Age and sex differences in hospitalized schizophrenics

  1978cited by this paper
• SPONTANEOUS BUCCOLINGUOFACIAL DYSKINESIA IN THE ELDERLY

  1977cited by this paper
• A survey of tardive dyskinesia in psychiatric outpatients.

  1977cited by this paper
• The assessment of tardive dyskinesia.

  1977cited by this paper
• The pathophysiologic basis of tardive dyskinesia.

  1977cited by this paper
• Oral choline administration to patients with tardive dyskinesia.

  1977cited by this paper
• Tardive dyskinesia: are first signs reversible?

  1977cited by this paper
• Baclofen (Lioresal®) in the treatment of neuroleptic‐induced tardive dyskinesia

  1976cited by this paper
• Haloperidol-induced tardive dyskinesia in monkeys

  1976cited by this paper
• The dopamine hypothesis of schizophrenia: a review.

  1976cited by this paper
• Persistent dyskinesia after long-term treatment with neuroleptics in Japan: its present status and clinical problems.

  1976cited by this paper
• Psychoactive drugs in mania. A controlled comparison of lithium carbonate, chlorpromazine, and haloperidol.

  1975cited by this paper
• Comparative Analysis of Persistent Dyskinesias of Long‐Term Usage With Neuroleptics in France and in Japan

  1975cited by this paper
• Overview: maintenance therapy in psychiatry: I. Schizophrenia.

  1975cited by this paper
• The antagonism of amphetamine-induced symptomatology by a neuroleptic.

  1974cited by this paper
• Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines.

  1974cited by this paper
• Tardive Dyskinesia: An Evaluation of the Etiologic Association with Neuroleptic Therapy

  1974cited by this paper
• Tardive and withdrawal dyskinesia associated with haloperidol.

  1974cited by this paper
• Chemotherapy in chronic organic brain syndrome--a review of the literature.

  1973cited by this paper
• Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine.

  1973cited by this paper
• Rapid tranquilization of acutely psychotic patients with intramuscular haloperidol and chlorpromazine.

  1973cited by this paper
• Persistence of Extra-pyramidal Disorders and Psychiatric Relapse after Withdrawal of Long-Term Phenothiazine Therapy

  1972cited by this paper
• Role of antidepressants and neuroleptics in the treatment of depression.

  1972cited by this paper
• Reserpine therapy of phenothiazine induced dyskinesia.

  1971cited by this paper
• Persistence of neurological symptoms due to neuroleptic drugs.

  1971cited by this paper
• The Significance of Brain Damage in Persistent Oral Dyskinesia

  1970cited by this paper
• NEUROPATHOLOGICAL INVESTIGATION OF 28 BRAINS FROM PATIENTS WITH DYSKINESIA

  1970cited by this paper
• PHENOTHIAZINE‐INDUCED DYSKINESIA IN NURSING‐HOME PATIENTS *

  1968cited by this paper
• Dyskinesia and neuroleptics.

  1968cited by this paper

• Antipsychotics and dietary interventions: Pharmacodynamics, pharmacokinetics, and synergisms in therapy.

  2025cites this paper
• Antipsychotics in Perspective: Past, Present, and Future.

  2024cites this paper
• Późne dyskinezy polekowe — rekomendacje grupy ekspertów: aktualizacja 2024

  2024cites this paper
• Antipsychotics in Perspective: Past, Present, and Future: Article 1 of 3.

  2024cites this paper
• Intra thecal baclofen pump as an ad hoc measure for a case of severe tardive dystonia refractory to multiple lesioning

  2023cites this paper
• Drug-Induced Movement Disorders

  2023cites this paper
• Non‐Parkinsonian movement disorders in the elderly

  2022cites this paper
• Antipsychotic Drug Development: From Historical Evidence to Fresh Perspectives

  2022cites this paper
• Neuroprotective effect of α‐pinene self‐emulsifying nanoformulation against 6‐OHDA induced neurotoxicity on human SH‐SY5Y cells and its in vivo validation for anti‐Parkinson's effect

  2021cites this paper
• Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel Recommendations

  2021cites this paper
• Medication-Related Problems in Surgical Patients

  2020cites this paper
• Olanzapine-Induced Tardive Blepharospasm: A Case Report

  2019cites this paper
• History of Psychopharmacology.

  2019cites this paper
• Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States

  2019cites this paper
• Antipsychotic-induced tardive dyskinesia: update on epidemiology and management

  2019cites this paper
• Extrapyramidové účinky léčiv – minimum pro farmaceuty

  2018cites this paper
• Tardive Dyskinesia: A Historical Perspective

  2017cites this paper
• The association between COMT Val158Met gene polymorphism and antipsychotic-induced tardive dyskinesia risk

  2016cites this paper
• Tetrabenazine: Spotlight on Drug Review

  2016cites this paper
• Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia

  2016cites this paper
• Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1

  2015cites this paper
• Withdrawal-Emergent Dyskinesias following Varenicline Therapy

  2015cites this paper
• Rates of diagnosis and treatment of neurological disorders within a prevalent population of community-dwelling elderly people in sub-Saharan Africa

  2012cites this paper
• Typical and atypical neuroleptics.

  2011cites this paper
• Comparative study between two animal models of extrapyramidal movement disorders: prevention and reversion by pecan nut shell aqueous extract.

  2011cites this paper
• A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis

  2011cites this paper
• Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs.

  2011cites this paper
• Spectrum of tardive syndromes: clinical recognition and management

  2010cites this paper
• Past and present progress in the pharmacologic treatment of schizophrenia.

  2010cites this paper
• Maintenance medication for chronic schizophrenics: risk/benefit assessment.

  2009cites this paper
• Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.

  2009cites this paper
• Lack of effect of antipsychotics on BNDF and NGF levels in hippocampus of Wistar rats

  2008cites this paper
• Tardive dyskinesia and glucid metabolism

  2007cites this paper
• Ilex paraguariensis has antioxidant potential and attenuates haloperidol-induced orofacial dyskinesia and memory dysfunction in rats

  2007cites this paper
• Drug-induced tardive motor syndromes.

  2007cites this paper
• Forty-five years of schizophrenia: personal reflections

  2006cites this paper
• Development of clinical methods for utilization review in psychiatric day treatment

  2006cites this paper
• Psychiatrists' Documentation of Informed Consent: A Representative Survey

  2006cites this paper
• Relapse prevention and recovery in the treatment of schizophrenia.

  2006cites this paper
• Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?

  2006cites this paper
• Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats.

  2005cites this paper
• Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and11C-raclopride

  2005cites this paper
• Movement disorders in the older patient: differential diagnosis and general management.

  2005cites this paper
• Effect of co-dergocrine mesylate on tardive dyskinesia a preliminary report

  2004cites this paper
• Treatment schedule as a determinant of the development of tolerance to haloperidol

  2004cites this paper
• Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal

  2004cites this paper
• Neuroleptic-induced striatal dopamine receptor supersensitivity in mice: Relationship to dose and drug

  2004cites this paper
• Assessing and Monitoring Antipsychotic-Induced Movement Disorders in Hospitalized Patients: A Cautionary Study

  2004cites this paper
• Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.

  2004cites this paper
• BAEP abnormalities in tardive dyskinesia

  2004cites this paper
• Drug-induced movement disorders.

  2004cites this paper
• A depot neuroleptic withdrawal study neurological effects

  2004cites this paper
• Implicit learning of visuospatial sequences in schizophrenia.

  2003cites this paper
• CLASSIFICATION AND TREATMENT OF TARDIVE SYNDROMES

  2003cites this paper
• Metoclopramide-Induced Supersensitivity Psychosis

  2002cites this paper
• Does peripheral neuropathy allow for the clinical expression of tardive dyskinesia by unmasking central nervous system changes?

  2001cites this paper
• Movement Disorders Induced by Dopamine Blocking Agents

  2001cites this paper
• 6-(4-Benzylpiperazin-1-yl)benzodioxanes as selective ligands at cloned primate dopamine D(4) receptors.

  2001cites this paper
• Good tolerability equals good results: the patient's perspective.

  2001cites this paper
• Extrapyramidal side effects are unacceptable.

  2001cites this paper
• Tardive dyskinesia

  2000cites this paper
• Patient satisfaction and acceptability of long-term treatment with quetiapine.

  1999cites this paper
• Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group.

  1999cites this paper
• Psychiatrists' Documentation of Informed Consent

  1998cites this paper
• Acute reserpine administration elicits long-term spontaneous oral dyskinesia.

  1997cites this paper
• Effect of alpha-methyl-para-tyrosine on response to cocaine challenge.

  1997cites this paper
• Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol

  1997cites this paper
• Informed Consent and Tardive Dyskinesia Long‐Term Follow‐up

  1996cites this paper
• Effects of amphetamine and 6-hydroxydopamine lesions on reserpine-induced oral dyskinesia.

  1996cites this paper
• Impaired motor skill learning in schizophrenia: implications for corticostriatal dysfunction.

  1996cites this paper
• Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol.

  1995cites this paper
• Rolipram, a selective c-AMP phosphodiesterase inhibitor suppresses oro-facial dyskinetic movements in rats.

  1995cites this paper
• Decision Analysis in Psychiatry

  1995cites this paper
• Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats: support for a model of tardive dyskinesia

  1994cites this paper
• Adverse Oral Effects of Systemic Drug Use

  1994cites this paper
• Effects of Neuroleptic Reduction in Schizophrenic Outpatients Receiving High Doses *

  1994cites this paper
• Movement Disorder in Never and Minimally Treated Nigerian Schizophrenic Patients

  1994cites this paper
• Drug treatment of resistant schizophrenia. Limitations and recommendations.

  1993cites this paper
• Postneuroleptic laryngeal dyskinesias: A cause of upper airway obstructive syndrome improved by local injections of botulinum toxin

  1993cites this paper
• PHARMACOLOGY OF PSYCHOTROPIC DRUGS USEFUL IN DERMATOLOGIC PRACTICE

  1993cites this paper
• Neuroleptic withdrawal psychosis in Tourette's disorder.

  1993cites this paper
• Neurochemical changes associated with the persistence of spontaneous oral dyskinesia in rats following chronic reserpine treatment.

  1991cites this paper
• Tardive Dyskinesia in Alzheimer's Disease: Clinical Features and Neuropathologic Correlates

  1991cites this paper
• Facial Dyskinesia: A 16–Year Follow-up Study

  1991cites this paper
• Tardive Dyskinesia in Elderly Psychiatric Patients in Singapore

  1991cites this paper
• Motor, Volitional and Behavioural Disorders in Schizophrenia

  1991cites this paper
• Tardive dyskinesia and chronic pain.

  1991cites this paper
• HLA antigens in tardive dyskinesia.

  1990cites this paper
• [Who are the patients treated in an outpatient clinic with high dosage neuroleptics?].

  1990cites this paper
• Qui Sont Les Patients Traités en Clinique Externe Avec des Doses Élevées de Neuroleptiques? *

  1990cites this paper
• Neuroleptic‐induced supersensitivity psychosis in patients with bipolar affective disorder

  1990cites this paper
• Dopaminergic alterations in cotreatments attenuating haloperidol-induced hypersensitivity.

  1990cites this paper
• Stiffness

  1989cites this paper
• Striatal dopamine D2 receptors in tardive dyskinesia: PET study.

  1989cites this paper
• Clinical Pharmacology of Antipsychotic Drugs

  1989cites this paper
• [Risk factors and prevention of tardive dyskinesias].

  1989cites this paper
• Abnormal Involuntary Movements

  1989cites this paper
• Facteurs de risque et prévention des dyskinésies tardives

  1989cites this paper
• Oral manifestations of drug therapy.

  1988cites this paper
• Haloperidol Decanoate: A Depot Antipsychotic

  1988cites this paper